| ［1］ Matsuda T, Marugame T. International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from Cancer Incidence in Five Continents Vol. VⅢ［J］. Jpn J Clin Oncol, 2007, 37(1): 74-75. ［2］ Randi G, Malvezzi M, Levi F, et al. Epidemiology of biliary tract cancers: an update［J］. Ann Oncol, 2009, 20(1): 146-159. ［3］ Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study［J］. J Clin Oncol, 2010, 28(30): 4581-4586. ［4］ BenMenachem T. Risk factors for cholangiocarcinoma［J］. Eur J Gastroenterol Hepatol, 2007, 19(8): 615-617. ［5］ Weigt J, Malfertheiner P. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer［J］. Expert Rev Gastroenterol, 2010, 4(4): 395-397. ［6］ Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan［J］. Br J Cancer, 2010, 103(4): 469-474. ［7］ Zhu AX, Hong TS, Hezel AF, et al. Current management of gallbladder carcinoma［J］. Oncologist, 2010, 15(2): 168-181. ［8］ Walter T, Horgan AM, McNamara M, et al. Feasibility and benefits of secondline chemotherapy in advanced biliary tract cancer: a large retrospective study［J］. Eur J Cancer, 2013, 49(2): 329-335. ［9］ Suzuki E, Ikeda M, Okusaka T, et al. A multicenter phase Ⅱ study of S1 for gemcitabinerefractory biliary tract cancer［J］. Cancer Chemother Pharmacol, 2013, 71(5): 1141-1146. ［10］ 龚新雷, 秦叔逵, 刘秀峰. 胆系肿瘤的内科治疗进展［J］. 临床肿瘤学杂志, 2013, 18(5): 459-467. ［11］ 刘斌, 崔洪尊, 高家森, 等. 紫杉醇对胆管癌细胞增殖及凋亡的影响［J］. 实用肿瘤学杂志, 2004, 18(4): 291-293. |
